scholarly journals Two-Phase Equation of State for Al2O3

2021 ◽  
Author(s):  
Kirill Velizhanin
2019 ◽  
Vol 150 (7) ◽  
pp. 074506 ◽  
Author(s):  
Philip C. Myint ◽  
Eric L. Shi ◽  
Sebastien Hamel ◽  
Hyunchae Cynn ◽  
Zsolt Jenei ◽  
...  

1967 ◽  
Vol 89 (4) ◽  
pp. 577-586 ◽  
Author(s):  
P. Cooper

A model is developed for analytically determining pump inducer performance in both the single-phase and cavitating flow regimes. An equation of state for vaporizing flow is used in an approximate, three-dimensional analysis of the flow field. The method accounts for losses and yields internal distributions of fluid pressure, velocity, and density together with the resulting overall efficiency and pressure rise. The results of calculated performance of two sample inducers are presented. Comparison with recent theory for fluid thermal effects on suction head requirements is made with the aid of a resulting dimensionless vaporization parameter.


2008 ◽  
Author(s):  
I. V. Lomonosov ◽  
Mark Elert ◽  
Michael D. Furnish ◽  
Ricky Chau ◽  
Neil Holmes ◽  
...  

2016 ◽  
Vol 13 (04) ◽  
pp. 1641010
Author(s):  
Yang-Yao Niu

In this paper, an unsteady preconditioning formulation for multi-phase flows with arbitrary equation of state based on the approximated Riemann solver is developed for multi-phase flows at all speed. This paper considers a homogeneous two-phase multi-equation mixture model with the assumption of kinematics and thermodynamics equilibriums. The thermodynamics behaviors of liquid phase, vapor phase and their phase transitional process are described by a temperature-dependent hybrid equation of state. Benchmark test cases, including one-dimensional (1D) condensation shock in the cavitated nozzle and two-dimensional (2D) cavitated blunt body problem, demonstrate accurate capturing of interfaces, shock waves and cavitation zones.


2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 133-133
Author(s):  
Bamidele Adesunloye ◽  
Wilfred Donald Stein ◽  
Julia Wilkerson ◽  
Xuan Huang ◽  
Fatima H Karzai ◽  
...  

133 Background: Like ATTP [bevacizumab + thalidomide + docetaxel + prednisone], ARTP [bevacizumab + lenalidomide + docetaxel + prednisone] is active in CRPC and in both the data suggest acquired resistance does not develop, supporting a strategy that continues therapy if tolerable. Discerning amongst new therapies in CRPC would be helped by novel assessment strategies that yield answers from smaller trials and allow comparisons across trials. We have validated a novel assessment method that quantifies tumor regression (d) and growth (g) rate constants using data obtained while pts are treated in a trial. We utilized this method to evaluate a phase II trial of ARTP in CRPC contrasting this with a previous study using thalidomide instead of lenalidomide (ATTP). Methods: Using PSA values and a two-phase mathematical equation we determined d and g. A three-phase equation was used to determine resistant fractions. Results: The median log g value with ARTP (-2.84) was statistically similar (p=0.204) to that observed with ATTP (-3.16). Both therapies had similar effects on log d (ARTP=-2.18; ATTP=-2.64; p=0.404). In a subset of pts with robust data both regimen are highly effective with only 3.01% and 5.46% of tumor resistant to ATTP and ARTP, respectively. In individual pt, statistically valid g and d values could be estimated after the fourth PSA value had been obtained, long before PSA increased - providing an early indicator of treatment failure. In most pts receiving prolonged treatment – as long as 700 d – the growth rate constant did not change, despite rising PSA values, indicating acquired resistance did not develop, and that if tolerable, therapy can be continued for longer periods of time. Conclusions: The substitution of daily thalidomide with lenalidomide 14/21 days in ARTP resulted in a combination statistically as effective as ATTP. As with ATTP majority of pts experienced marked reductions in the tumor’s g, and surprisingly in most, there was no evidence of acquired resistance, g remaining unchanged over prolonged time periods. Given the tolerability of this combination, pts with marked reductions in g may benefit from prolonged ARTP therapy.


Sign in / Sign up

Export Citation Format

Share Document